Literature DB >> 30015656

Unfavorable Structural and Functional Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis.

Ilijas Jelcic1, James V M Hanson, Sebastian Lukas, Konrad P Weber, Klara Landau, Misha Pless, Markus Reindl, Michael Weller, Roland Martin, Andreas Lutterotti, Sven Schippling.   

Abstract

BACKGROUND: Recurrent optic neuritis (rON) associated with myelin oligodendrocyte glycoprotein (MOG)-specific antibodies has been initially reported to show a better clinical outcome than aquaporin-4 (AQP4)-seropositive ON in neuromyelitis optica spectrum disorder (NMOSD). Here, we characterize clinical and neuroimaging findings in severe cases of MOG antibody-positive and AQP4 antibody-negative bilateral rON.
METHODS: Three male adults with rON (ages 18, 44, and 63 years) were evaluated with optical coherence tomography (OCT), MRI, cerebrospinal fluid (CSF), and serological studies.
RESULTS: All patients experienced >7 relapses of ON with severe reduction of visual acuity and partial response to steroid treatment. Optic nerves were affected bilaterally, although unilateral relapses were more frequent than simultaneous bilateral recurrences. Patients were MOG-seropositive but repeatedly tested negative for AQP4 antibodies. OCT showed severe thinning of the peripapillary retinal nerve fiber layer. On MRI, contrast-enhancing lesions extended over more than half the length of the optic nerve. CSF analyses during ON episodes were normal. Severe visual deficits accumulated over time in 2 of 3 patients, despite immunosuppressive therapy.
CONCLUSIONS: MOG-seropositive and AQP4-seronegative rON may be associated with an aggressive disease course and poor functional and structural outcomes. In contrast to previous reports, the severity and pattern of retinal and optic nerve damage closely resembled phenotypes commonly observed in AQP4-seropositive rON without fulfilling current diagnostic criteria for NMOSD.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30015656     DOI: 10.1097/WNO.0000000000000669

Source DB:  PubMed          Journal:  J Neuroophthalmol        ISSN: 1070-8022            Impact factor:   3.042


  4 in total

Review 1.  Myelin Oligodendrocyte Glycoprotein-Associated Disorders.

Authors:  Erin Longbrake
Journal:  Continuum (Minneap Minn)       Date:  2022-08-01

Review 2.  Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis.

Authors:  Nadja Borisow; Masahiro Mori; Satoshi Kuwabara; Michael Scheel; Friedemann Paul
Journal:  Front Neurol       Date:  2018-10-23       Impact factor: 4.003

3.  Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies.

Authors:  Elisabeth Maillart; Françoise Durand-Dubief; Céline Louapre; Bertrand Audoin; Bertrand Bourre; Nathalie Derache; Jonathan Ciron; Nicolas Collongues; Jérome de Sèze; Mikael Cohen; Christine Lebrun-Frenay; Nawel Hadhoum; Hélène Zéphir; Romain Deschamps; Clarisse Carra-Dallière; Pierre Labauge; Philippe Kerschen; Alexis Montcuquet; Sandrine Wiertlewski; David Laplaud; Gwenaëlle Runavot; Sandra Vukusic; Caroline Papeix; Romain Marignier
Journal:  J Neuroinflammation       Date:  2020-04-23       Impact factor: 8.322

4.  Differences in morphology and visual function of myelin oligodendrocyte glycoprotein antibody and multiple sclerosis associated optic neuritis.

Authors:  Rino Vicini; Dominik Brügger; Mathias Abegg; Anke Salmen; Hilary Michelle Grabe
Journal:  J Neurol       Date:  2020-08-12       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.